Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
34
BIXT Quote, Financials, Valuation and Earnings
Last price:
$0.0400
Seasonality move
:
-4.64%
Day range:
$0.0350 - $0.0417
52-week range:
$0.0262 - $0.2283
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
35.48x
P/B ratio:
--
Volume:
1.3M
Avg. volume:
616.4K
1-year change:
-72.67%
Market cap:
$3.9M
Revenue:
--
EPS (TTM):
-$0.02
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BIXT
BioXyTran, Inc.
|
-- | -- | -- | -- | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$305.2M | $0.12 | 15.35% | -21.66% | $31.85 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.3B | $2.14 | 88.89% | -58.59% | $449.32 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$952.5M | $1.10 | 3.04% | 4.71% | $88.87 |
|
IMNN
Imunon, Inc.
|
-- | -$0.86 | -- | -53.91% | $21.50 |
|
SVRA
Savara, Inc.
|
-- | -$0.14 | -- | -12.28% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BIXT
BioXyTran, Inc.
|
$0.0407 | -- | $3.9M | -- | $0.00 | 0% | 35.48x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.20 | $31.85 | $3.8B | 9.65x | $0.00 | 0% | 3.49x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$318.85 | $449.32 | $41B | 141.27x | $0.00 | 0% | 11.46x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$55.50 | $88.87 | $10.3B | 31.15x | $0.00 | 0% | 3.33x |
|
IMNN
Imunon, Inc.
|
$3.22 | $21.50 | $7.4M | -- | $0.00 | 0% | 16.43x |
|
SVRA
Savara, Inc.
|
$5.56 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BIXT
BioXyTran, Inc.
|
-92.59% | -1.977 | 21.95% | 0.00x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 2.895 | 1.15% | 3.40x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.662 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.55% | -0.343 | 5.63% | 3.25x |
|
IMNN
Imunon, Inc.
|
21.26% | 7.808 | 10.13% | 1.25x |
|
SVRA
Savara, Inc.
|
12.84% | -1.345 | 2.43% | 11.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BIXT
BioXyTran, Inc.
|
-$4.2K | -$500.2K | -- | -- | -- | -$34.7K |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$614.5M | $99.8M | 5.33% | 5.89% | 11.16% | $56.6M |
|
IMNN
Imunon, Inc.
|
-$167K | -$3.5M | -282.76% | -365% | -- | -$4.4M |
|
SVRA
Savara, Inc.
|
-$40K | -$33.4M | -67.27% | -80.59% | -- | -$25.1M |
BioXyTran, Inc. vs. Competitors
-
Which has Higher Returns BIXT or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to BioXyTran, Inc.'s net margin of 96.33%. BioXyTran, Inc.'s return on equity of -- beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital BIXTBioXyTran, Inc.-- -$0.00 -$1.5M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About BIXT or ACAD?
BioXyTran, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.85 which suggests that it could grow by 43.47%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than BioXyTran, Inc., analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than BioXyTran, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIXTBioXyTran, Inc.0 0 0 ACADACADIA Pharmaceuticals, Inc.12 4 1 -
Is BIXT or ACAD More Risky?
BioXyTran, Inc. has a beta of 2.512, which suggesting that the stock is 151.212% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.833, suggesting its less volatile than the S&P 500 by 16.67%.
-
Which is a Better Dividend Stock BIXT or ACAD?
BioXyTran, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXyTran, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIXT or ACAD?
BioXyTran, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. BioXyTran, Inc.'s net income of -$282.7K is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, BioXyTran, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 9.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXyTran, Inc. is 35.48x versus 3.49x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIXTBioXyTran, Inc.35.48x -- -- -$282.7K ACADACADIA Pharmaceuticals, Inc.3.49x 9.65x $284M $273.6M
-
Which has Higher Returns BIXT or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to BioXyTran, Inc.'s net margin of 16.99%. BioXyTran, Inc.'s return on equity of -- beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital BIXTBioXyTran, Inc.-- -$0.00 -$1.5M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About BIXT or ALNY?
BioXyTran, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $449.32 which suggests that it could grow by 40.92%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than BioXyTran, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than BioXyTran, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIXTBioXyTran, Inc.0 0 0 ALNYAlnylam Pharmaceuticals, Inc.14 8 0 -
Is BIXT or ALNY More Risky?
BioXyTran, Inc. has a beta of 2.512, which suggesting that the stock is 151.212% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.387, suggesting its less volatile than the S&P 500 by 61.27%.
-
Which is a Better Dividend Stock BIXT or ALNY?
BioXyTran, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXyTran, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIXT or ALNY?
BioXyTran, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. BioXyTran, Inc.'s net income of -$282.7K is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, BioXyTran, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 141.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXyTran, Inc. is 35.48x versus 11.46x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIXTBioXyTran, Inc.35.48x -- -- -$282.7K ALNYAlnylam Pharmaceuticals, Inc.11.46x 141.27x $1.1B $186.4M
-
Which has Higher Returns BIXT or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -- compared to BioXyTran, Inc.'s net margin of -5.2%. BioXyTran, Inc.'s return on equity of -- beat BioMarin Pharmaceutical, Inc.'s return on equity of 5.89%.
Company Gross Margin Earnings Per Share Invested Capital BIXTBioXyTran, Inc.-- -$0.00 -$1.5M BMRNBioMarin Pharmaceutical, Inc.68.65% -$0.24 $6.7B -
What do Analysts Say About BIXT or BMRN?
BioXyTran, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 60.13%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than BioXyTran, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than BioXyTran, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIXTBioXyTran, Inc.0 0 0 BMRNBioMarin Pharmaceutical, Inc.14 5 0 -
Is BIXT or BMRN More Risky?
BioXyTran, Inc. has a beta of 2.512, which suggesting that the stock is 151.212% more volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.293, suggesting its less volatile than the S&P 500 by 70.697%.
-
Which is a Better Dividend Stock BIXT or BMRN?
BioXyTran, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXyTran, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIXT or BMRN?
BioXyTran, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $895M. BioXyTran, Inc.'s net income of -$282.7K is higher than BioMarin Pharmaceutical, Inc.'s net income of -$46.6M. Notably, BioXyTran, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 31.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXyTran, Inc. is 35.48x versus 3.33x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIXTBioXyTran, Inc.35.48x -- -- -$282.7K BMRNBioMarin Pharmaceutical, Inc.3.33x 31.15x $895M -$46.6M
-
Which has Higher Returns BIXT or IMNN?
Imunon, Inc. has a net margin of -- compared to BioXyTran, Inc.'s net margin of --. BioXyTran, Inc.'s return on equity of -- beat Imunon, Inc.'s return on equity of -365%.
Company Gross Margin Earnings Per Share Invested Capital BIXTBioXyTran, Inc.-- -$0.00 -$1.5M IMNNImunon, Inc.-- -$1.16 $5.2M -
What do Analysts Say About BIXT or IMNN?
BioXyTran, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Imunon, Inc. has an analysts' consensus of $21.50 which suggests that it could grow by 567.7%. Given that Imunon, Inc. has higher upside potential than BioXyTran, Inc., analysts believe Imunon, Inc. is more attractive than BioXyTran, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIXTBioXyTran, Inc.0 0 0 IMNNImunon, Inc.3 1 0 -
Is BIXT or IMNN More Risky?
BioXyTran, Inc. has a beta of 2.512, which suggesting that the stock is 151.212% more volatile than S&P 500. In comparison Imunon, Inc. has a beta of 2.127, suggesting its more volatile than the S&P 500 by 112.653%.
-
Which is a Better Dividend Stock BIXT or IMNN?
BioXyTran, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXyTran, Inc. pays -- of its earnings as a dividend. Imunon, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIXT or IMNN?
BioXyTran, Inc. quarterly revenues are --, which are smaller than Imunon, Inc. quarterly revenues of --. BioXyTran, Inc.'s net income of -$282.7K is higher than Imunon, Inc.'s net income of -$3.4M. Notably, BioXyTran, Inc.'s price-to-earnings ratio is -- while Imunon, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXyTran, Inc. is 35.48x versus 16.43x for Imunon, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIXTBioXyTran, Inc.35.48x -- -- -$282.7K IMNNImunon, Inc.16.43x -- -- -$3.4M
-
Which has Higher Returns BIXT or SVRA?
Savara, Inc. has a net margin of -- compared to BioXyTran, Inc.'s net margin of --. BioXyTran, Inc.'s return on equity of -- beat Savara, Inc.'s return on equity of -80.59%.
Company Gross Margin Earnings Per Share Invested Capital BIXTBioXyTran, Inc.-- -$0.00 -$1.5M SVRASavara, Inc.-- -$0.13 $233M -
What do Analysts Say About BIXT or SVRA?
BioXyTran, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 94.47%. Given that Savara, Inc. has higher upside potential than BioXyTran, Inc., analysts believe Savara, Inc. is more attractive than BioXyTran, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BIXTBioXyTran, Inc.0 0 0 SVRASavara, Inc.6 0 0 -
Is BIXT or SVRA More Risky?
BioXyTran, Inc. has a beta of 2.512, which suggesting that the stock is 151.212% more volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.316, suggesting its less volatile than the S&P 500 by 68.412%.
-
Which is a Better Dividend Stock BIXT or SVRA?
BioXyTran, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioXyTran, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIXT or SVRA?
BioXyTran, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. BioXyTran, Inc.'s net income of -$282.7K is higher than Savara, Inc.'s net income of -$32.2M. Notably, BioXyTran, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioXyTran, Inc. is 35.48x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIXTBioXyTran, Inc.35.48x -- -- -$282.7K SVRASavara, Inc.-- -- -- -$32.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 5
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 5
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 5
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
